News

BMJ5d
Treatment of primary Sjögren’s syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity
Objectives To evaluate the efficacy and safety of ianalumab (VAY736), a B cell-depleting, B cell activating factor receptor-blocking, monoclonal antibody, in patients with active primary Sjögren’s ...
BMJ5d
Comparative analysis of SGLT-2 expression in renal vasculitis and lupus nephritis - Annals of the Rheumatic Diseases
The nephroprotective efficacy of sodium-glucose cotransporter-2 (SGLT-2) inhibitors (SGLT-2i) in patients with chronic kidney disease, with or without type 2 diabetes, has already been described.1 ...
BMJ1d
POS0255 A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY COMPARING EFFICACY OF DOTINURAD AND FEBUXOSTAT FOR THE TREATMENT OF GOUT IN CHINESE SUBJECTS - Annals of the ...
Background: Gout is increasingly common disease in China. Dotinurad is a novel, selective urate reabsorption inhibitor, which reduces serum uric acid levels by selective inhibition of the urate ...
BMJ4d
Oral sildenafil for the treatment of Raynaud’s phenomenon and digital ulcers secondary to systemic sclerosis - Annals of the Rheumatic Diseases
Raynaud’s phenomenon (RP) with or without digital ulcer formation is a significant cause of morbidity for patients with systemic sclerosis (SSc, scleroderma). Lichtenstein reported oral sildenafil as ...